Jonathan D. Schwartz
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, DNA Repair Mechanisms, CRISPR and Genetic Engineering, Angiogenesis and VEGF in Cancer, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial(2014)2,435 cited
- → Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial(2013)2,179 cited
- → Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial(2015)838 cited
- → Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma(2008)507 cited
- → Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis(2004)459 cited
- → Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials(2002)255 cited
- → Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu(2004)190 cited
- → Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia(2019)173 cited
- → A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer(2013)164 cited
- → Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial(2016)144 cited